Cargando…
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
We describe melphalan pharmacokinetics in 26 patients treated by isolated limb perfusion (ILP). Group A (n = 11) were treated with a bolus of melphalan (1.5 mg kg-1), and in a phase I study the dose was increased to 1.75 mg kg-1. The higher dose was given as a bolus to Group B (n = 9), and by divide...
Autores principales: | Scott, R. N., Kerr, D. J., Blackie, R., Hughes, J., Burnside, G., MacKie, R. M., Byrne, D. S., McKay, A. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977921/ https://www.ncbi.nlm.nih.gov/pubmed/1637666 |
Ejemplares similares
-
Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018) -
Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994) -
Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007) -
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma
por: Modi, Sachin, et al.
Publicado: (2022) -
Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases
por: Ruschulte, Heiner, et al.
Publicado: (2013)